Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and nitrocefin

levofloxacin has been researched along with nitrocefin in 3 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(nitrocefin)		Trials
(nitrocefin)		Recent Studies (post-2010) (nitrocefin)
4,3465812,209203056

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A1
Blais, J; Chamberland, S; Cho, D; Fronko, R; Galazzo, J; Hecker, S; Hoshino, K; Ishida, H; Lee, A; Lee, M; Lee, VJ; Leger, R; Lomovskaya, O; Renau, T; Warren, MS; Watkins, W1
Bohnert, JA; Handzlik, J; Kaczor, A; Karcz, T; Kern, WV; Kieć-Kononowicz, K; Olejarz, A; Schuster, S1

Other Studies

3 other study(ies) available for levofloxacin and nitrocefin

ArticleYear
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship

2009
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:1

    Topics: Anti-Infective Agents; Bacterial Outer Membrane Proteins; Carrier Proteins; Cephalosporins; Dipeptides; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Levofloxacin; Magnetic Resonance Spectroscopy; Membrane Transport Proteins; Microbial Sensitivity Tests; Ofloxacin; Plasmids; Pseudomonas aeruginosa

2001
Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Assay; Biological Transport; Cell Membrane; Cephalosporins; Clarithromycin; Drug Synergism; Escherichia coli; Escherichia coli Proteins; Fluorescent Dyes; Gene Expression; Imidazoles; Indicators and Reagents; Kinetics; Levofloxacin; Linezolid; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Oxacillin; Piperazines; Protein Kinases; Repressor Proteins; Rifampin

2016